Article
Integrating Imaging, Histologic, and Genetic Features to Predict Tumor Mutation Burden of Non-Small-Cell Lung Cancer.
Clinical lung cancer - 1 May 2020
Zhang Nasha, Wu Jia, Yu Jinming, Zhu Hui, Yang Ming, Li Ruijiang
Abstract excerpt
BACKGROUND: Immune checkpoint inhibitors have dramatically changed the landscape of therapeutic management of non-small-cell lung cancer (NSCLC). Tumor mutation burden (TMB) is an important biomarker of the response to cancer immunotherapy. We investigated the relationship between TMB and the imaging, histologic, and genetic features in NSCLC. MATERIALS AND METHODS: We evaluated the associations between the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
